Center for Scientific Review; Notice of Closed Meetings, 29447 [2014-11807]

Download as PDF Federal Register / Vol. 79, No. 99 / Thursday, May 22, 2014 / Notices *Mail: Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE., MS F–57, Atlanta, Ga. 30333 Instructions: All submissions must include the agency name and docket number for this notice. All relevant comments will be posted without change. This means that no confidential business information or other confidential information should be submitted in response to this notice. Refer to the section Submission of Nominations (below) for the specific information required. For further information, please contact Commander Jessilynn B. Taylor, Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE., MS F–57, Atlanta, Ga. 30333, Email: tpcandidatecomments@cdc.gov; phone: 1–800–232–4636. FOR FURTHER INFORMATION CONTACT: The Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund) [42 U.S.C. 9601 et seq.] establishes certain requirements for ATSDR and the U.S. Environmental Protection Agency (EPA) with regard to hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the Priority List of Hazardous Substances. This list identifies 275 hazardous substances that ATSDR and EPA have determined pose the most significant current potential threat to human health. The revised list of the 275 priority substances is available at www.atsdr.cdc.gov/SPL. For prior versions of the list of substances, see www.atsdr.cdc.gov/SPL/resources. SUPPLEMENTARY INFORMATION: www.atsdr.cdc.gov/toxprofiles/ index.asp. Submission of Nominations for the Evaluation of Set 28 Proposed Substances: Today’s notice invites voluntary public nominations for substances included on the SPL and for substances not listed on the SPL. All nominations should include the full name of the nominator, affiliation, email address. When nominating a non-SPL substance, please include the rationale for the nomination. Please note that email addresses will not be posted on regulations.gov. ATSDR will evaluate all data and information associated with nominated substances and will determine the final list of substances to be chosen for toxicological profile development. Substances will be chosen according to ATSDR’s specific guidelines for selection. These guidelines can be found in the Selection Criteria announced in the Federal Register on May 7, 1993 (58FR27286–27287). A hard copy of the selection criteria is available upon request or may be accessed at the following Web site: https://www.atsdr. cdc.gov/toxprofiles/guidance/criteria_ for_selecting_tp_support.pdf. Please ensure that your comments are submitted within the specified nomination period. Nominations received after the closing date will be marked as late and may be considered only if time and resources permit. Sascha Chaney, Acting Director, Office of Policy, Planning and Evaluation, National Center for Environmental Health/Agency for Toxic, Substances and Disease Registry. [FR Doc. 2014–11848 Filed 5–21–14; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES mstockstill on DSK4VPTVN1PROD with NOTICES Each year, ATSDR develops a list of substances to be considered for toxicological profile development. The Set 28 nomination process includes consideration of all substances on ATSDR’s Priority List of Hazardous Substances, also known as the Substance Priority List (SPL), as well as other substances nominated by the public. The 275 substances on the SPL will be considered for Set 28 Toxicological Profile development. This list may be found at the following Web site: www.atsdr.cdc.gov/SPL and in the docket at www.regulations.gov. Existing Toxicological Profiles may be found at the following Web site: https:// Center for Scientific Review; Notice of Closed Meetings Jkt 232001 Name of Committee: Infectious Diseases and Microbiology Integrated Review Group Clinical Research and Field Studies of Infectious Diseases Study Section. Date: June 16, 2014. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Kabuki, 1625 Post Street, San Francisco, CA 94115. Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301–435– 0903, saadisoh@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel Primate Skeletal Database. Date: June 19, 2014. Time: 12:00 p.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Daniel F. McDonald, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4110, MSC 7814, Bethesda, MD 20892, (301) 435– 1215, mcdonald@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: May 16, 2014. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–11807 Filed 5–21–14; 8:45 am] BILLING CODE 4140–01–P Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health 21:05 May 21, 2014 would constitute a clearly unwarranted invasion of personal privacy. BILLING CODE 4163–70–P Substances to be Evaluated for Set 28 Toxicological Profiles VerDate Mar<15>2010 29447 National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which E:\FR\FM\22MYN1.SGM 22MYN1

Agencies

[Federal Register Volume 79, Number 99 (Thursday, May 22, 2014)]
[Notices]
[Page 29447]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-11807]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Infectious Diseases and Microbiology 
Integrated Review Group Clinical Research and Field Studies of 
Infectious Diseases Study Section.
    Date: June 16, 2014.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hotel Kabuki, 1625 Post Street, San Francisco, CA 94115.
    Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301-435-
0903, saadisoh@csr.nih.gov.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel Primate Skeletal Database.
    Date: June 19, 2014.
    Time: 12:00 p.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Daniel F. McDonald, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4110, MSC 7814, Bethesda, MD 
20892, (301) 435-1215, mcdonald@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: May 16, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-11807 Filed 5-21-14; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.